An Open-label, Crossover, Interventional Phase IV Study to Compare the Ease of Use of TIP With Nebulized TIS and Nebulized COLI for the Treatment of Pulmonary Pseudomonas Aeruginosa (P.a) in Patients With Cystic Fibrosis
Phase of Trial: Phase IV
Latest Information Update: 21 Jun 2019
Price : $35 *
At a glance
- Drugs Tobramycin (Primary) ; Colistimethate sodium; Tobramycin
- Indications Cystic fibrosis; Pseudomonal infections
- Focus Therapeutic Use
- Sponsors Novartis
- 21 Jun 2019 Trial has been completed in UK, according to European Clinical Trials Database record.
- 05 Dec 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record.
- 04 Nov 2014 Planned End Date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.